Results for tag: "Pyoderma Gangrenosum Drug"

Pyoderma Gangrenosum (PG) is a rare, chronic, and potentially life-threatening skin disorder that is caused by an abnormal immune response. It is characterized by the formation of deep ulcers on the skin, which can be painful and difficult to treat. Treatment for PG typically involves the use of immune-modulating drugs, such as corticosteroids, immunosuppressants, and biologics. These drugs are used to reduce inflammation and suppress the immune system, allowing the ulcers to heal. In addition, antibiotics may be prescribed to prevent infection. The Pyoderma Gangrenosum Drug market is composed of a variety of pharmaceutical companies that specialize in the development and manufacture of drugs for the treatment of PG. These companies include AbbVie, Amgen, AstraZeneca, Bristol-Myers Squibb, Eli Lilly, GlaxoSmithKline, Janssen, Merck, Novartis, Pfizer, and Roche. Show Less Read more